Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

46.20 +0.26 (+0.56%)

Streaming Delayed Price Updated: 10:32 AM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

82 83 Next >

What's going on in today's session: S&P500 movers ↗

April 09, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.

Via Chartmill

These S&P500 stocks are gapping in today's session ↗

April 09, 2025

Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.

Via Chartmill

Tech Stocks Rebound As US Treasuries Tumble: What's Driving Markets Wednesday? ↗

April 09, 2025

Wall Street saw a tentative tech rebound early Wednesday, as investors begin to shrug off escalating U.S.-China trade tensions following a steep market selloff.

Via Benzinga

Topics World Trade

FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients ↗

April 09, 2025

The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase 3 CheckMate-8HW trial results.

Via Benzinga

Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗

April 09, 2025

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.

Via Investor's Business Daily

Topics Government Stocks World Trade

Bristol Myers Wins Dismissal Of Class Action Lawsuit Accusing It Of Fraudulently Acquiring Patents – Retail Sentiment Remains Subdued ↗

April 09, 2025

U.S. District Judge Edgardo Ramos in Manhattan said the plaintiffs failed to show that Bristol Myers and Celgene Corp violated the federal Sherman antitrust law.

Via Stocktwits

Topics Fraud Government Intellectual Property

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields ↗

April 04, 2025

Via Benzinga

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

April 08, 2025

From Bristol Myers Squibb

Via Business Wire

Is Pfizer Stock a Buy? ↗

April 03, 2025

Via The Motley Fool

Topics Intellectual Property

Laser-Focus on These Tariff-Proof Stocks Before It’s Too Late ↗

April 02, 2025

Stay calm amid tariff uncertainty with low-valued pharma and European stocks. Discover why these sectors offer protection and potential gains.

Via InvestorPlace

Topics Government Intellectual Property World Trade

Is Bristol Myers Squibb's High-Yielding Dividend Safe? ↗

April 02, 2025

Via The Motley Fool

Topics Intellectual Property

Exploring the top movers within the S&P500 index during today's session. ↗

April 01, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday.

Via Chartmill

Is Bristol-Myers Squibb Gaining or Losing Market Support? ↗

April 01, 2025

Via Benzinga

Beat the S&P 500 With This Cash-Gushing Dividend Stock ↗

April 01, 2025

Via The Motley Fool

Topics Intellectual Property Stocks

BMY: A High-Yielding Drug Stock With Great Growth Potential ↗

April 01, 2025

Bristol-Myers Squibb Co. traces its corporate beginnings back to 1887. Today, the company is a leader in developing innovative drugs like Eliquis for stroke prevention and Opdivo for cancer...

Via Talk Markets

Topics Stocks / Equities

Exploring the top movers within the S&P500 index during today's session. ↗

March 31, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.

Via Chartmill

5 Ways to Prepare for AI’s ‘Tower of Terror’ Moment ↗

March 30, 2025

As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025.

Via InvestorPlace

Topics Artificial Intelligence Economy Government

50-Year-Old Early Retiree Making $175,000 in Dividends Shares Portfolio - 'Now I Spend on Travel, Cars and Doing What I Want' ↗

March 28, 2025

Via Benzinga

Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...

March 28, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

March 28, 2025

From Bristol Myers Squibb

Via Business Wire

The 5-Letter Word Every Investor Should Memorize to Win in 2025 ↗

March 27, 2025

As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025.

Via InvestorPlace

Topics Economy World Trade

3 Deeply Discounted Dividend Stocks to Buy Today ↗

March 27, 2025

Via The Motley Fool

Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

March 27, 2025

EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks

March 27, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors ↗

March 26, 2025

Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer.

Via Benzinga

1 Large-Cap Stock on Our Watchlist and 2 to Brush Off

March 26, 2025

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

Via StockStory

Topics Retirement

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

March 24, 2025

Via Benzinga

BRISTOL-MYERS SQUIBB CO (NYSE:BMY): good value for what you're paying. ↗

March 24, 2025

BRISTOL-MYERS SQUIBB CO may be an undervalued stock option. NYSE:BMY retains a strong financial foundation and an attractive price tag.

Via Chartmill

The Stock Market Hates Uncertainty & Loves To Climb A Wall-Of-Worry ↗

March 21, 2025

In this video lesson, I review the overall market and a new swing position for Monday's session.

Via Talk Markets

Topics ETFs Stocks / Equities

10 Health Care Stocks Whale Activity In Today's Session ↗

March 21, 2025

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

82 83 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Bristol-Myers Squibb (NY:BMY)

All News about Bristol-Myers Squibb

Starting at $3.75/week.

Subscribe Today